{"id":"meglutol","rwe":[],"tags":[{"label":"meglutol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","category":"target"},{"label":"HMGCR","category":"gene"},{"label":"C10AX05","category":"atc"},{"label":"Active","category":"status"},{"label":"Anticholesteremic Agents","category":"pharmacology"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","category":"pharmacology"},{"label":"Hypolipidemic Agents","category":"pharmacology"},{"label":"Lipid Regulating Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"mevalon","offLabel":[],"synonyms":["meglutol","dicrotalic acid","lipoglutaren","medroglutaric acid","mevalon","CB-337"],"timeline":[],"aiSummary":"Mevalon (MEGLUTOL) is a small molecule drug that targets 3-hydroxy-3-methylglutaryl-coenzyme A reductase, an enzyme involved in cholesterol synthesis. It is classified as a meglutol and works by inhibiting this enzyme, thereby reducing the production of cholesterol in the liver. However, due to the lack of available information, its commercial status, approved indications, half-life, bioavailability, and generic manufacturers are unknown. As a result, its use and safety considerations cannot be fully assessed. Further research is needed to determine its potential as a therapeutic agent.","approvals":[],"brandName":"Mevalon","ecosystem":[],"mechanism":{"target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","targets":[{"gene":"HMGCR","source":"DrugCentral","target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","protein":"3-hydroxy-3-methylglutaryl-coenzyme A reductase"}],"modality":"Small Molecule","drugClass":"meglutol","explanation":"Think of your liver like a factory that makes cholesterol. Mevalon is like a traffic cop that stops the factory from producing too much cholesterol by blocking the enzyme that helps make it. This can help lower cholesterol levels in the blood.","oneSentence":"Mevalon works by blocking an enzyme that helps produce cholesterol in the liver.","technicalDetail":"Mevalon specifically targets 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), the rate-limiting enzyme in the mevalonate pathway, which is responsible for cholesterol biosynthesis in the liver."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1670","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MEGLUTOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MEGLUTOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:33:26.082211","biosimilars":[],"competitors":[{"drugName":"dextrothyroxine","drugSlug":"dextrothyroxine","fdaApproval":"1967-04-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"probucol","drugSlug":"probucol","fdaApproval":"1977-02-01","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ezetimibe","drugSlug":"ezetimibe","fdaApproval":"2002-10-25","patentExpiry":"Apr 30, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"mipomersen","drugSlug":"mipomersen","fdaApproval":"2013-01-29","patentExpiry":"Jan 29, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lomitapide","drugSlug":"lomitapide","fdaApproval":"2012-12-21","patentExpiry":"Aug 19, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"evolocumab","drugSlug":"evolocumab","fdaApproval":"2015-08-28","relationship":"same-class"},{"drugName":"alirocumab","drugSlug":"alirocumab","fdaApproval":"2015-07-24","relationship":"same-class"},{"drugName":"bempedoic acid","drugSlug":"bempedoic-acid","fdaApproval":"2020-02-21","patentExpiry":"Mar 14, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"inclisiran","drugSlug":"inclisiran","fdaApproval":"2021-12-22","patentExpiry":"May 10, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"evinacumab","drugSlug":"evinacumab","fdaApproval":"2021-02-11","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"meglutol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dextrothyroxine","brandName":"dextrothyroxine","genericName":"dextrothyroxine","approvalYear":"1967","relationship":"same-class"},{"drugId":"probucol","brandName":"probucol","genericName":"probucol","approvalYear":"1977","relationship":"same-class"},{"drugId":"ezetimibe","brandName":"ezetimibe","genericName":"ezetimibe","approvalYear":"2002","relationship":"same-class"},{"drugId":"mipomersen","brandName":"mipomersen","genericName":"mipomersen","approvalYear":"2013","relationship":"same-class"},{"drugId":"lomitapide","brandName":"lomitapide","genericName":"lomitapide","approvalYear":"2012","relationship":"same-class"},{"drugId":"evolocumab","brandName":"evolocumab","genericName":"evolocumab","approvalYear":"2015","relationship":"same-class"},{"drugId":"alirocumab","brandName":"alirocumab","genericName":"alirocumab","approvalYear":"2015","relationship":"same-class"},{"drugId":"bempedoic-acid","brandName":"bempedoic acid","genericName":"bempedoic acid","approvalYear":"2020","relationship":"same-class"},{"drugId":"inclisiran","brandName":"inclisiran","genericName":"inclisiran","approvalYear":"2021","relationship":"same-class"},{"drugId":"evinacumab","brandName":"evinacumab","genericName":"evinacumab","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04512404","phase":"","title":"Endothelial Microparticles as Potential Biomarkers of Endothelial Dysfunction","status":"COMPLETED","sponsor":"Universiti Sains Malaysia","startDate":"2016-10-13","conditions":["Endothelial Dysfunction"],"enrollment":48,"completionDate":"2022-05-01"},{"nctId":"NCT01631409","phase":"","title":"Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy","status":"WITHDRAWN","sponsor":"City Hospital No 40, Saint Petersburg, Russia","startDate":"2013-09","conditions":["Coronary Heart Disease (CHD)"],"enrollment":0,"completionDate":"2021-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"CLA99KCD53","CHEBI":"CHEBI:16831","INN_ID":"4448","UMLSCUI":"C0000402","ChEMBL_ID":"CHEMBL50444","KEGG_DRUG":"D04897","DRUGBANK_ID":"DB04377","PDB_CHEM_ID":"MAH","PUBCHEM_CID":"1662","IUPHAR_LIGAND_ID":"2960","MESH_DESCRIPTOR_UI":"D015093"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":8,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C10AX05","allCodes":["C10AX05"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}